# A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

> **NCT05385692** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Locally Advanced or Metastatic Digestive Tract Tumors
- Solid Tumor

## Interventions

- **DRUG:** BL-M02D1

## Key facts

- **NCT ID:** NCT05385692
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385692, "A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05385692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*